QURE News and Press, uniQure N.V.

2026-06-28 08:45:00 ET The last time I spoke about REGENXBIO (RGNX), it was with respect to a Seeking Alpha article entitled " Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results ." With respect to this article, I mentioned that the company had received a complet...

2026-06-24 12:38:33 ET More on Regenxbio, uniQure, etc. Moderna: Flu Vaccine Progress Is Only Part Of The Story Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade) Moderna: The Comeback Is Now In Full Swing uniQure prices upsized $225M public offe...

2026-06-24 08:41:07 ET More on uniQure UniQure: AMT-130's FDA Path Reaffirms My Bull Case uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring uniQure: Why A Shifting FDA Could Change Everything For AMT-130 uniQure files $150M proposed public ...

LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,05...

2026-06-22 16:06:56 ET More on uniQure UniQure: AMT-130's FDA Path Reaffirms My Bull Case uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring uniQure: Why A Shifting FDA Could Change Everything For AMT-130 uniQure soars as Cantor upgrades on ...

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinar...

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing tr...

2026-06-18 15:28:24 ET The last time I spoke about Biohaven ( BHVN ) it was with a Seeking Alpha article entitled " Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 ." With respect to this article, I mentioned that the company had achieved a comp...

2026-06-18 10:06:55 ET ... Read the full article on Seeking Alpha For further details see: UniQure: AMT-130's FDA Path Reaffirms My Bull Case

2026-06-18 09:48:51 ET Investment Overview - Sarepta's Tough 2025 Explained The stock of Sarepta Therapeutics, Inc. ( SRPT ) made a gain of ~7.5% yesterday, rising to a value of ~$17 per share; however, the stock remains down >20% year-to-date and down >75% on a five-year ...